Navigation Links
eResearchTechnology Reports Third Quarter 2008 Results
Date:10/30/2008

ion of CCSS into eRT;

-- The Company's tax rate was 35.8% for the third quarter of 2008, which included the effect of certain tax benefits realized, compared to 37.7% for the third quarter of 2007;

-- New bookings were $43.0 million compared to $35.5 million for the third quarter of 2007, an increase of 21.1%;

-- New bookings included seven new Thorough ECG study agreements, valued at an average of slightly greater than $1 million each;

-- The backlog was $159.2 million, compared to $157.9 million at June 30, 2008.

-- The book-to-bill ratio was 1.3 in the third quarter of 2008, compared to 1.4 in the second quarter of 2008; and

-- eRT ended the third quarter with $62.4 million in cash, cash equivalents, and investments, an increase of $6.5 million from $55.9 million at June 30, 2008. For the three months ended September 30, 2008, net cash provided by operating activities was $8.8 million.

Other recent highlights:

-- The cancellation rate was an annualized 19.6% as compared to 18.1% in the second quarter of 2008. The cancellation rate is calculated as the sum of the actual value of study cancellations plus studies that are completed at amounts under the original contracted amount divided by beginning backlog. The increase in the cancellation rate was caused by a number of long-term projects ending without completion of the full number of contracted ECGs.

-- We successfully completed the integration of the CCSS acquisition with the complete transfer of all operating activities from the CCSS Reno facility into our operations in Philadelphia and Peterborough, UK; and

-- We are on track for the move of our corporate headquarters (and US- based core lab) in Philadelphia to a larger facility, also in Philadelphia, by the end of 2008.

Financial highlights for the first nine months of 2008:

-- For the nine months ended September 30, 2008, the Company reported net revenues of $103.1 million co
'/>"/>

SOURCE eResearchTechnology, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related biology technology :

1. eResearchTechnology to Present at the Thomas Weisel Healthcare Conference 2007 on September 5th
2. eResearchTechnology to Present at the UBS Global Healthcare Services Conference 2008 on February 11th
3. eResearchTechnology, Inc. to Announce 2007 Fourth Quarter Results on February 26, 2008
4. eResearchTechnology Reports Fourth Quarter and Full Year 2007 Results
5. eResearchTechnology, Inc. and nSpire Health, Inc. Form Alliance to Deliver Integrated Cardiac Safety and Pulmonary Clinical Trial Services
6. eResearchTechnology, Inc. to Announce 2008 First Quarter Results on May 5, 2008
7. eResearchTechnology to Present at the Deutsche Bank 33rd Annual Healthcare Conference on May 7th 2008
8. eResearchTechnology Reports First Quarter 2008 Results
9. eResearchTechnology Announces Resignation of its CFO
10. eResearchTechnology to Present at the FBR 12th Annual Spring Investor Conference on May 28th 2008
11. eResearchTechnology Names New Chief Financial Officer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/11/2014)... 11, 2014 /PRNewswire-iReach/ -- Maxim Peptide, a website that ... used solely in scientific experiments, is currently celebrating its ... business, Maxim Peptide, which was created by the founders ... and updated website that now features a special deals ... updated with fascinating articles about peptide research, including a ...
(Date:7/11/2014)... 11, 2014 EPFL and the University of  ... appointment of John P. Donoghue . The American ... Geneva . The new Wyss Center ... Geneva , has named as its ... John P. Donoghue , founder of Brown University,s Institute ...
(Date:7/10/2014)... 2014 Women in the West ... an additional family planning option. Sayana® Press has ... all levels of the health system and in ... widely used contraceptive—Pfizer’s Depo-Provera® (depot medroxyprogesterone acetate)—with the ... the first of four African countries expected to ...
(Date:7/10/2014)... Terascala, the industry leader in HPC management ... vice president of product management for Flexera Software, has ... Terascala’s software when combined with leading compute and storage ... and most reliable solutions for processing big data. , ... and broaden its product portfolio. His leadership in startups ...
Breaking Biology Technology:Maxim Peptide Celebrates Second Anniversary Online with an Updated Website and Special Deals Section 2John P. Donoghue is Taking the Lead at the Wyss Center and is Appointed Professor at EPFL and University of Geneva 2John P. Donoghue is Taking the Lead at the Wyss Center and is Appointed Professor at EPFL and University of Geneva 3Injectable Contraceptive Launched in Burkina Faso to Expand Choice and Address Unmet Need 2Injectable Contraceptive Launched in Burkina Faso to Expand Choice and Address Unmet Need 3Injectable Contraceptive Launched in Burkina Faso to Expand Choice and Address Unmet Need 4Injectable Contraceptive Launched in Burkina Faso to Expand Choice and Address Unmet Need 5Injectable Contraceptive Launched in Burkina Faso to Expand Choice and Address Unmet Need 6Terascala Expands Executive Team 2Terascala Expands Executive Team 3
... ALS Lab Presents on Therapy Development StrategyCAMBRIDGE, Mass., ... (ALS TDI) has announced the 2009 launch of ... two-hour, interactive seminar is designed to inform and ... worldwide efforts to discover and develop effective treatments ...
... -- Genesis,Pharmaceuticals Enterprises, Inc. (OTC Bulletin Board: GNPH) ("Genesis" ... operations in the,People,s Republic of China, today announced its ... 2009 ended December 31, 2008. , , ... -- Revenue was $32.9 million, up 24.1% ...
... potential) of stem cells and accelerates development of ... announces today the introduction of its GT(TM) Flow ... Summit to be held in New York, NY. ... validated, scalable technology for customizing the biological activity ...
Cached Biology Technology:Seminar Will Bring ALS Researchers to Patient Groups 2Seminar Will Bring ALS Researchers to Patient Groups 3Genesis Pharmaceuticals Reports Results for the Second Quarter of its Fiscal Year 2009 2Genesis Pharmaceuticals Reports Results for the Second Quarter of its Fiscal Year 2009 3Genesis Pharmaceuticals Reports Results for the Second Quarter of its Fiscal Year 2009 4Genesis Pharmaceuticals Reports Results for the Second Quarter of its Fiscal Year 2009 5Genesis Pharmaceuticals Reports Results for the Second Quarter of its Fiscal Year 2009 6Genesis Pharmaceuticals Reports Results for the Second Quarter of its Fiscal Year 2009 7Genesis Pharmaceuticals Reports Results for the Second Quarter of its Fiscal Year 2009 8Genesis Pharmaceuticals Reports Results for the Second Quarter of its Fiscal Year 2009 9Genesis Pharmaceuticals Reports Results for the Second Quarter of its Fiscal Year 2009 10Genesis Pharmaceuticals Reports Results for the Second Quarter of its Fiscal Year 2009 11Genesis Pharmaceuticals Reports Results for the Second Quarter of its Fiscal Year 2009 12Genesis Pharmaceuticals Reports Results for the Second Quarter of its Fiscal Year 2009 13Genesis Pharmaceuticals Reports Results for the Second Quarter of its Fiscal Year 2009 14Genesis Pharmaceuticals Reports Results for the Second Quarter of its Fiscal Year 2009 15Genesis Pharmaceuticals Reports Results for the Second Quarter of its Fiscal Year 2009 16MaxCyte Introduces the GT(TM) Flow Transfection System for Application with Autologous and Allogeneic Stem Cell Therapies 2MaxCyte Introduces the GT(TM) Flow Transfection System for Application with Autologous and Allogeneic Stem Cell Therapies 3
(Date:7/13/2014)... French . ... project, led by the Research Institute of the McGill ... new oral medication is showing significant progress in restoring ... now, this inherited retinal disease that causes visual impairment ... untreatable. The study is published today in the scientific ...
(Date:7/11/2014)... 2014--Researchers at the Department of Energy,s Oak Ridge ... presented by R&D Magazine in recognition of the ... recognize the tremendous value of our National Labs," ... development at the National Labs continues to help ... the scientific and technological innovations necessary to remain ...
(Date:7/11/2014)... Research awarded Michael F. Holick, PhD, MD, of Boston ... V. Avioli Award. Holick, a professor of medicine, physiology ... the understanding of vitamin D and its role in ... of the American Society for Bone and Mineral Research ... research. It is named for ASBMR,s first president and ...
Breaking Biology News(10 mins):MUHC researcher unveils novel treatment for a form of childhood blindness 2ORNL wins eight R&D 100s 2ORNL wins eight R&D 100s 3ORNL wins eight R&D 100s 4BUSM's Michael F. Holick receives American Society for Bone and Mineral Research award 2
... for more than 50 years as one of the ... disorder. However, scientists have never been entirely sure ... from Cardiff University scientists suggests a possible mechanism for ... of the illness and potentially more effective treatments. ...
... obese people become salt sensitive and hypertensive has been ... They,ve documented a chain of events in which excess ... to retain more sodium and, consequently, more fluid and ... cardiologist at MCG,s Georgia Prevention Institute. Their findings ...
... carbon dioxide continues to burgeon in the atmosphere causing the ... to remove the excess gas from the atmosphere and store ... Gislason of the University of Iceland has been studying the ... basalt and presented his findings today to several thousand geochemists ...
Cached Biology News:Connection elucidated between obesity, salt sensitivity and high blood pressure 2Storing carbon dioxide deep underground in rock form 2
...
...
...
DryStrip aligners, 4. Category: Electrophoresis Systems & Standards & Reagents, IEF & SDS-PAGE & 2-D Electrophoresis, Multiphor II Kits & Components and Accessories....
Biology Products: